Semaglutide patent protection ends in Canada, the first G7 country
Canada's semaglutide patent lapse opens the door to generic Ozempic and Wegovy there, but US patients still face protection until at least 2031.
Semaglutide's core patent protection lapsed in Canada on January 4, 2026, making Canada the first G7 country where patents covering the molecule itself have expired [1]. Semaglutide is the active ingredient in the Ozempic and Wegovy injections and in the oral tablet Rybelsus, all made by Novo Nordisk [2].
Generic drugmakers moved quickly. Sandoz, Apotex, Teva and Aspen filed generic semaglutide applications in Canada [1]. Those filings have not yet translated into supply: no generic semaglutide approval in Canada has been announced, and no launch date has been disclosed. One industry analysis describes generic semaglutide as launching in Canada during 2026 [1], while Canadian approvals have lagged behind the patent lapse.
Canada's lapse was not a patent term simply running out. A core patent there was allowed to lapse, according to the intellectual property firm Reddie & Grose [2]. The same core patents remain in force in the US, Europe and Japan, which have patent term extension mechanisms that can prolong protection [2]. In the US, the original compound patent (No. 8,536,122) has a nominal expiration of March 20, 2026, but a second patent extended through patent term adjustment and patent term extension pushes effective protection to December 5, 2031 [1]. Novo Nordisk has filed 320 US patent applications for semaglutide, with 154 granted and follow-on patents extending potential protection to 2042, 16 years beyond the original compound patent [1]. Novo Nordisk's projected US revenue during the 2026 to 2031 extension period is estimated at $166 billion [1].
Canada is the first of several markets. Core semaglutide patents expire in China, India and Brazil in 2026, with March 2026 the expected date outside Canada [1][2]. About a quarter of the world's obese population is thought to live in India and China [2]. Novo Nordisk is enforcing its rights elsewhere: in Europe it obtained 26 preliminary injunctions in October 2025 under patent EP1863839 [2]. European loss of exclusivity is expected in 2031 [2].
An expired core patent does not clear the road by itself. Novo Nordisk holds many secondary patents covering formulations, dosing regimens, delivery devices and specific indications [1][2]. Generic companies can try to design around them, seek approval only for non-patented uses through so-called skinny labels, or challenge the patents in court or at patent offices. Europe's Boards of Appeal revoked three semaglutide patents toward the end of 2024, while two others were upheld at first instance [2].
Why it matters for patients
For US patients, nothing about supply or price changes right now. Generic semaglutide sold in Canada, India, China or Brazil cannot legally be imported into the United States [1]. Semaglutide costs more than $1,000 per month in the US without insurance, and tirzepatide (Mounjaro, Zepbound) is priced similarly [1].
Tirzepatide's main compound patent does not expire until January 2036, with follow-on patents extending protection to 2041 [1]. The one GLP-1 already available as a generic in the US is liraglutide, which launched at about $1,165 per month against brand Saxenda at $1,300 to $1,800, a saving of roughly $135 to $200 per month at the wholesale level, with larger price drops expected as more manufacturers enter [1]. Liraglutide is a first-generation GLP-1 with more modest weight loss than semaglutide or tirzepatide [1].
What happens next
- March 2026: core semaglutide patents expire in China, India and Brazil [1][2].
- March 20, 2026: nominal US expiration date on semaglutide's original compound patent [1].
- May 13, 2026: the date from which patent challenges become eligible for tirzepatide, potentially extended by six months if pediatric exclusivity is granted [1].
- December 5, 2031: effective US protection for semaglutide runs to this date, with follow-on patents to 2042 [1]. European loss of exclusivity is also expected in 2031 [2].
- January 2036: tirzepatide's compound patent expires, with follow-on protection to 2041 [1].
Whether Canadian generics reach pharmacy shelves before those dates, and at what price, has not been disclosed.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.